P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease

Abstract

Background Vedolizumab (VDZ) is approved for treatment of Crohn's disease (CD) and ulcerative colitis (UC). Reports on clinical response and remission in registration trials and real world cohorts have shown efficacy, however, data on endoscopic response are limited. In this study, we aimed to assess endoscopic response and remission at week 16 and 52. Methods Adult patients with CD, UC and IBD unclassified (IBDU) who started VDZ between October '14 and July '16 were prospectively included. Endoscopic disease activity was assessed at baseline, week 16 and week 52 using the simple endoscopic score (SES) in CD, Rutgeerts score for postoperative CD and MAYO score in UC and IBDU. Endoscopic scoring was randomly performed and blinded for patient characteristics and time points. Endoscopic response was defined as SES-CD reduction >=50%, Rutgeerts score reduction of >=1 and MAYO score reduction of >=1. Endoscopic remission was defined as SES-CD <4 or Rutgeerts score